APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global RNA Vaccines Industry Growth and Trends Forecast to 2032

22 December 2025108 pages

Choose your research edition.

Industry ResearchRNA Vaccines Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA Vaccines Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal RNA Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA Vaccines Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA Vaccines Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global RNA Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of RNA Vaccines include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global RNA Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The RNA Vaccines market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global RNA Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to RNA Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global RNA Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

RNA Vaccines Market by Company

Translate Bio

Tiba Biotechnology

Sangamo Therapeutics

Moderna Therapeutics

In-Cell-Art

Ethris

eTheRNA

CureVac

BioNTech

Argos Therapeutics

RNA Vaccines Segment by Type

Individualized Cancer Treatment MRNA Vaccine

Infection Prevention MRNA Vaccine

Infectious Disease Treatment MRNA Vaccine

RNA Vaccines Segment by Application

Infectious Disease

Cancer

Other

RNA Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of RNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Individualized Cancer Treatment MRNA Vaccine Table 2. Major Company of Infection Prevention MRNA Vaccine Table 3. Major Company of Infectious Disease Treatment MRNA Vaccine Table 4. Global RNA Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global RNA Vaccines Sales by Type (2021-2026) & (k units) Table 6. Global RNA Vaccines Sales Market Share in Volume by Type (2021-2026) Table 7. Global RNA Vaccines Sales by Type (2021-2026) & (US$ Million) Table 8. Global RNA Vaccines Sales Market Share in Value by Type (2021-2026) Table 9. Global RNA Vaccines Price by Type (2021-2026) & (US$/unit) Table 10. Global RNA Vaccines Sales by Type (2027-2032) & (k units) Table 11. Global RNA Vaccines Sales Market Share in Volume by Type (2027-2032) Table 12. Global RNA Vaccines Sales by Type (2027-2032) & (US$ Million) Table 13. Global RNA Vaccines Sales Market Share in Value by Type (2027-2032) Table 14. Global RNA Vaccines Price by Type (2027-2032) & (US$/unit) Table 15. North America RNA Vaccines Sales by Type (2021-2026) & (k units) Table 16. North America RNA Vaccines Sales by Type (2021-2026) & (US$ Million) Table 17. Europe RNA Vaccines Sales by Type (2021-2026) & (k units) Table 18. Europe RNA Vaccines Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific RNA Vaccines Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific RNA Vaccines Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America RNA Vaccines Sales by Type (2021-2026) & (k units) Table 22. Latin America RNA Vaccines Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa RNA Vaccines Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa RNA Vaccines Sales by Type (2021-2026) & (US$ Million) Table 25. RNA Vaccines Industry Trends Table 26. RNA Vaccines Industry Drivers Table 27. RNA Vaccines Industry Opportunities and Challenges Table 28. RNA Vaccines Industry Restraints Table 29. Global RNA Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global RNA Vaccines Revenue Market Share by Company (2021-2026) Table 31. Global RNA Vaccines Sales by Company (2021-2026) & (k units) Table 32. Global RNA Vaccines Sales Share by Company (2021-2026) Table 33. Global RNA Vaccines Market Price by Company (2021-2026) & (US$/unit) Table 34. Global RNA Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global RNA Vaccines Major Company Production Sites and Headquarters Table 36. Global RNA Vaccines Company, Product Type & Application Table 37. Global RNA Vaccines Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global RNA Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global RNA Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global RNA Vaccines Sales by Region (2021-2026) & (k units) Table 42. Global RNA Vaccines Sales Market Share in Volume by Region (2021-2026) Table 43. Global RNA Vaccines Sales by Region (2021-2026) & (US$ Million) Table 44. Global RNA Vaccines Sales Market Share in Value by Region (2021-2026) Table 45. Global RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Global RNA Vaccines Sales by Region (2027-2032) & (k units) Table 47. Global RNA Vaccines Sales Market Share in Volume by Region (2027-2032) Table 48. Global RNA Vaccines Sales by Region (2027-2032) & (US$ Million) Table 49. Global RNA Vaccines Sales Market Share in Value by Region (2027-2032) Table 50. Global RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 51. Global RNA Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global RNA Vaccines Sales by Application (2021-2026) & (k units) Table 53. Global RNA Vaccines Sales Market Share in Volume by Application (2021-2026) Table 54. Global RNA Vaccines Sales by Application (2021-2026) & (US$ Million) Table 55. Global RNA Vaccines Sales Market Share in Value by Application (2021-2026) Table 56. Global RNA Vaccines Price by Application (2021-2026) & (US$/unit) Table 57. Global RNA Vaccines Sales by Application (2027-2032) & (k units) Table 58. Global RNA Vaccines Sales Market Share in Volume by Application (2027-2032) Table 59. Global RNA Vaccines Sales by Application (2027-2032) & (US$ Million) Table 60. Global RNA Vaccines Sales Market Share in Value by Application (2027-2032) Table 61. Global RNA Vaccines Price by Application (2027-2032) & (US$/unit) Table 62. North America RNA Vaccines Sales by Application (2021-2026) & (k units) Table 63. North America RNA Vaccines Sales by Application (2021-2026) & (US$ Million) Table 64. Europe RNA Vaccines Sales by Application (2021-2026) & (k units) Table 65. Europe RNA Vaccines Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific RNA Vaccines Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific RNA Vaccines Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America RNA Vaccines Sales by Application (2021-2026) & (k units) Table 69. Latin America RNA Vaccines Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa RNA Vaccines Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa RNA Vaccines Sales by Application (2021-2026) & (US$ Million) Table 72. Translate Bio Company Information Table 73. Translate Bio Business Overview Table 74. Translate Bio RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Translate Bio RNA Vaccines Product Portfolio Table 76. Translate Bio Recent Development Table 77. Tiba Biotechnology Company Information Table 78. Tiba Biotechnology Business Overview Table 79. Tiba Biotechnology RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Tiba Biotechnology RNA Vaccines Product Portfolio Table 81. Tiba Biotechnology Recent Development Table 82. Sangamo Therapeutics Company Information Table 83. Sangamo Therapeutics Business Overview Table 84. Sangamo Therapeutics RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Sangamo Therapeutics RNA Vaccines Product Portfolio Table 86. Sangamo Therapeutics Recent Development Table 87. Moderna Therapeutics Company Information Table 88. Moderna Therapeutics Business Overview Table 89. Moderna Therapeutics RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Moderna Therapeutics RNA Vaccines Product Portfolio Table 91. Moderna Therapeutics Recent Development Table 92. In-Cell-Art Company Information Table 93. In-Cell-Art Business Overview Table 94. In-Cell-Art RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. In-Cell-Art RNA Vaccines Product Portfolio Table 96. In-Cell-Art Recent Development Table 97. Ethris Company Information Table 98. Ethris Business Overview Table 99. Ethris RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Ethris RNA Vaccines Product Portfolio Table 101. Ethris Recent Development Table 102. eTheRNA Company Information Table 103. eTheRNA Business Overview Table 104. eTheRNA RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. eTheRNA RNA Vaccines Product Portfolio Table 106. eTheRNA Recent Development Table 107. CureVac Company Information Table 108. CureVac Business Overview Table 109. CureVac RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. CureVac RNA Vaccines Product Portfolio Table 111. CureVac Recent Development Table 112. BioNTech Company Information Table 113. BioNTech Business Overview Table 114. BioNTech RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. BioNTech RNA Vaccines Product Portfolio Table 116. BioNTech Recent Development Table 117. Argos Therapeutics Company Information Table 118. Argos Therapeutics Business Overview Table 119. Argos Therapeutics RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Argos Therapeutics RNA Vaccines Product Portfolio Table 121. Argos Therapeutics Recent Development Table 122. North America RNA Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 123. North America RNA Vaccines Sales by Country (2021-2026) & (k units) Table 124. North America RNA Vaccines Sales Market Share by Country (2021-2026) Table 125. North America RNA Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 126. North America RNA Vaccines Sales Market Share Forecast by Country (2027-2032) Table 127. North America RNA Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. North America RNA Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 129. North America RNA Vaccines Market Share by Country (2021-2026) Table 130. North America RNA Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. North America RNA Vaccines Market Share Forecast by Country (2027-2032) Table 132. Europe RNA Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 133. Europe RNA Vaccines Sales by Country (2021-2026) & (k units) Table 134. Europe RNA Vaccines Sales Market Share by Country (2021-2026) Table 135. Europe RNA Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 136. Europe RNA Vaccines Sales Market Share Forecast by Country (2027-2032) Table 137. Europe RNA Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Europe RNA Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 139. Europe RNA Vaccines Market Share by Country (2021-2026) Table 140. Europe RNA Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Europe RNA Vaccines Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific RNA Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific RNA Vaccines Sales by Country (2021-2026) & (k units) Table 144. Asia-Pacific RNA Vaccines Sales Market Share by Country (2021-2026) Table 145. Asia-Pacific RNA Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 146. Asia-Pacific RNA Vaccines Sales Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific RNA Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific RNA Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 149. Asia-Pacific RNA Vaccines Market Share by Country (2021-2026) Table 150. Asia-Pacific RNA Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Asia-Pacific RNA Vaccines Market Share Forecast by Country (2027-2032) Table 152. Latin America RNA Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 153. Latin America RNA Vaccines Sales by Country (2021-2026) & (k units) Table 154. Latin America RNA Vaccines Sales Market Share by Country (2021-2026) Table 155. Latin America RNA Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 156. Latin America RNA Vaccines Sales Market Share Forecast by Country (2027-2032) Table 157. Latin America RNA Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Latin America RNA Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 159. Latin America RNA Vaccines Market Share by Country (2021-2026) Table 160. Latin America RNA Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Latin America RNA Vaccines Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa RNA Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa RNA Vaccines Sales by Country (2021-2026) & (k units) Table 164. Middle East and Africa RNA Vaccines Sales Market Share by Country (2021-2026) Table 165. Middle East and Africa RNA Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 166. Middle East and Africa RNA Vaccines Sales Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa RNA Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa RNA Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 169. Middle East and Africa RNA Vaccines Market Share by Country (2021-2026) Table 170. Middle East and Africa RNA Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Middle East and Africa RNA Vaccines Market Share Forecast by Country (2027-2032) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. RNA Vaccines Distributors List Table 175. RNA Vaccines Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. RNA Vaccines Image Figure 2. Global RNA Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global RNA Vaccines Sales (2021-2032) & (k units) Figure 5. Individualized Cancer Treatment MRNA Vaccine Image Figure 6. Global Individualized Cancer Treatment MRNA Vaccine Sales YoY Growth (2021-2032) & (k units) Figure 7. Infection Prevention MRNA Vaccine Image Figure 8. Global Infection Prevention MRNA Vaccine Sales YoY Growth (2021-2032) & (k units) Figure 9. Infectious Disease Treatment MRNA Vaccine Image Figure 10. Global Infectious Disease Treatment MRNA Vaccine Sales YoY Growth (2021-2032) & (k units) Figure 11. Global RNA Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global RNA Vaccines Market Share by Type 2025 VS 2032 Figure 13. North America RNA Vaccines Sales Market Share in Volume by Type in 2025 Figure 14. North America RNA Vaccines Sales Market Share in Value by Type in 2025 Figure 15. Europe RNA Vaccines Sales Market Share in Volume by Type in 2025 Figure 16. Europe RNA Vaccines Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific RNA Vaccines Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific RNA Vaccines Sales Market Share in Value by Type in 2025 Figure 19. Latin America RNA Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. Latin America RNA Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa RNA Vaccines Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa RNA Vaccines Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 RNA Vaccines Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Infectious Disease Image Figure 26. Global Infectious Disease Sales YoY Growth (2021-2032) & (k units) Figure 27. Cancer Image Figure 28. Global Cancer Sales YoY Growth (2021-2032) & (k units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 31. Global RNA Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global RNA Vaccines Market Share by Application 2025 VS 2032 Figure 33. North America RNA Vaccines Sales Market Share in Volume by Application in 2025 Figure 34. North America RNA Vaccines Sales Market Share in Value by Application in 2025 Figure 35. Europe RNA Vaccines Sales Market Share in Volume by Application in 2025 Figure 36. Europe RNA Vaccines Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific RNA Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific RNA Vaccines Sales Market Share in Value by Application in 2025 Figure 39. Latin America RNA Vaccines Sales Market Share in Volume by Application in 2025 Figure 40. Latin America RNA Vaccines Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa RNA Vaccines Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa RNA Vaccines Sales Market Share in Value by Application in 2025 Figure 43. North America RNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America RNA Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America RNA Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe RNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe RNA Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe RNA Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific RNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific RNA Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific RNA Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America RNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America RNA Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America RNA Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa RNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa RNA Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa RNA Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. RNA Vaccines Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. RNA Vaccines Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Individualized Cancer Treatment MRNA Vaccine
  • Infection Prevention MRNA Vaccine
  • Infectious Disease Treatment MRNA Vaccine
Applications
  • Infectious Disease
  • Cancer
  • Other
Companies covered
  • Translate Bio
  • Tiba Biotechnology
  • Sangamo Therapeutics
  • Moderna Therapeutics
  • In-Cell-Art
  • Ethris
  • eTheRNA
  • CureVac
  • BioNTech
  • Argos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global RNA Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global RNA Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 RNA Vaccines Market by Type
  6. 1.3.1 Individualized Cancer Treatment MRNA Vaccine
  7. 1.3.2 Infection Prevention MRNA Vaccine
  8. 1.3.3 Infectious Disease Treatment MRNA Vaccine
  9. 1.4 Global RNA Vaccines Market Size by Type
  10. 1.4.1 Global RNA Vaccines Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global RNA Vaccines Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global RNA Vaccines Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America RNA Vaccines Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe RNA Vaccines Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific RNA Vaccines Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America RNA Vaccines Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa RNA Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 RNA Vaccines Industry Trends
  2. 2.2 RNA Vaccines Industry Drivers
  3. 2.3 RNA Vaccines Industry Opportunities and Challenges
  4. 2.4 RNA Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by RNA Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by RNA Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by RNA Vaccines Price (2021-2026)
  4. 3.4 Global RNA Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global RNA Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global RNA Vaccines Company, Product Type & Application
  7. 3.7 Global RNA Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global RNA Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 RNA Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 RNA Vaccines Tier 1, Tier 2, and Tier 3
4 RNA Vaccines Regional Status and Outlook
  1. 4.1 Global RNA Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global RNA Vaccines Historic Market Size by Region
  3. 4.2.1 Global RNA Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global RNA Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global RNA Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global RNA Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global RNA Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global RNA Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global RNA Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 RNA Vaccines by Application
  1. 5.1 RNA Vaccines Market by Application
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global RNA Vaccines Market Size by Application
  6. 5.2.1 Global RNA Vaccines Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global RNA Vaccines Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global RNA Vaccines Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America RNA Vaccines Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe RNA Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific RNA Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America RNA Vaccines Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa RNA Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Translate Bio
  2. 6.1.1 Translate Bio Company Information
  3. 6.1.2 Translate Bio Business Overview
  4. 6.1.3 Translate Bio RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Translate Bio RNA Vaccines Product Portfolio
  6. 6.1.5 Translate Bio Recent Developments
  7. 6.2 Tiba Biotechnology
  8. 6.2.1 Tiba Biotechnology Company Information
  9. 6.2.2 Tiba Biotechnology Business Overview
  10. 6.2.3 Tiba Biotechnology RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Tiba Biotechnology RNA Vaccines Product Portfolio
  12. 6.2.5 Tiba Biotechnology Recent Developments
  13. 6.3 Sangamo Therapeutics
  14. 6.3.1 Sangamo Therapeutics Company Information
  15. 6.3.2 Sangamo Therapeutics Business Overview
  16. 6.3.3 Sangamo Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sangamo Therapeutics RNA Vaccines Product Portfolio
  18. 6.3.5 Sangamo Therapeutics Recent Developments
  19. 6.4 Moderna Therapeutics
  20. 6.4.1 Moderna Therapeutics Company Information
  21. 6.4.2 Moderna Therapeutics Business Overview
  22. 6.4.3 Moderna Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Moderna Therapeutics RNA Vaccines Product Portfolio
  24. 6.4.5 Moderna Therapeutics Recent Developments
  25. 6.5 In-Cell-Art
  26. 6.5.1 In-Cell-Art Company Information
  27. 6.5.2 In-Cell-Art Business Overview
  28. 6.5.3 In-Cell-Art RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 In-Cell-Art RNA Vaccines Product Portfolio
  30. 6.5.5 In-Cell-Art Recent Developments
  31. 6.6 Ethris
  32. 6.6.1 Ethris Company Information
  33. 6.6.2 Ethris Business Overview
  34. 6.6.3 Ethris RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Ethris RNA Vaccines Product Portfolio
  36. 6.6.5 Ethris Recent Developments
  37. 6.7 eTheRNA
  38. 6.7.1 eTheRNA Company Information
  39. 6.7.2 eTheRNA Business Overview
  40. 6.7.3 eTheRNA RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 eTheRNA RNA Vaccines Product Portfolio
  42. 6.7.5 eTheRNA Recent Developments
  43. 6.8 CureVac
  44. 6.8.1 CureVac Company Information
  45. 6.8.2 CureVac Business Overview
  46. 6.8.3 CureVac RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 CureVac RNA Vaccines Product Portfolio
  48. 6.8.5 CureVac Recent Developments
  49. 6.9 BioNTech
  50. 6.9.1 BioNTech Company Information
  51. 6.9.2 BioNTech Business Overview
  52. 6.9.3 BioNTech RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 BioNTech RNA Vaccines Product Portfolio
  54. 6.9.5 BioNTech Recent Developments
  55. 6.10 Argos Therapeutics
  56. 6.10.1 Argos Therapeutics Company Information
  57. 6.10.2 Argos Therapeutics Business Overview
  58. 6.10.3 Argos Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Argos Therapeutics RNA Vaccines Product Portfolio
  60. 6.10.5 Argos Therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America RNA Vaccines Sales by Country
  2. 7.1.1 North America RNA Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America RNA Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America RNA Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America RNA Vaccines Market Size by Country
  6. 7.2.1 North America RNA Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America RNA Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America RNA Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe RNA Vaccines Sales by Country
  2. 8.1.1 Europe RNA Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe RNA Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe RNA Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe RNA Vaccines Market Size by Country
  6. 8.2.1 Europe RNA Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe RNA Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe RNA Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific RNA Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific RNA Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific RNA Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific RNA Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific RNA Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific RNA Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific RNA Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific RNA Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America RNA Vaccines Sales by Country
  2. 10.1.1 South America RNA Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America RNA Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America RNA Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America RNA Vaccines Market Size by Country
  6. 10.2.1 South America RNA Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America RNA Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America RNA Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa RNA Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa RNA Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa RNA Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa RNA Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa RNA Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa RNA Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa RNA Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa RNA Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 RNA Vaccines Value Chain Analysis
  2. 12.1.1 RNA Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 RNA Vaccines Production Mode & Process
  7. 12.2 RNA Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 RNA Vaccines Distributors
  10. 12.2.3 RNA Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst